Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR2 mutant |
| Therapy | Sunitinib |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR2 mutant | Advanced Solid Tumor | predicted - sensitive | Sunitinib | Phase II | Actionable | In a Phase II trial (TAPUR), Sutent (sunitinib) treatment resulted in a disease control rate of 39% (11/28) and an objective response rate of 11% (3/28, all partial responses (PR)) in advanced solid tumor patients harboring FGFR2 alterations including mutation (n=19), amplification (amp) (n=2), fusion (n=2), mutation and amp (n=4), or fusion, mutation, and amp (n=1), with 2 PR in lung cancer and 1 PR in uterine cancer harboring FGFR2 mutations (Cancer Res (2025) 85 (8_Supplement_2): CT226). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Abstract CT226: Sunitinib (S) in patients (pts) with solid tumors with FGFR2 alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study | Full reference... |